GFM
SION

GF Fund Management’s Sionna Therapeutics SION Stock Holding History

GF Fund Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.2K Buy
1,003
+127
+14% +$4.85K ﹤0.01% 424
2025
Q4 		$36K Buy
+876
New +$33.2K ﹤0.01% 437

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GF Fund Management's SION Position: Q1 2026 in Review

GF Fund Management increased its Sionna Therapeutics (SION) stake by 14% in Q1 2026, buying an estimated $4.85K and bringing the position to 1,003 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

GF Fund Management first reported a position in SION in Q4 2025 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • GF Fund Management held 1,003 shares of Sionna Therapeutics worth $40.2K as of Q1 2026.
  • GF Fund Management bought 127 Sionna Therapeutics shares in Q1 2026, an estimated $4.85K.
  • Sionna Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #424 holding.
  • GF Fund Management first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.